Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsInitiationPrice Target
Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.
Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.